

# Balaxi Pharmaceuticals Limited

April 12, 2023

To,  
Listing Department,  
National Stock Exchange of India Limited  
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051

**NSE Symbol: BALAXI**

Dear Sir/Madam,

**Subject: Non – applicability of disclosure requirements specified under Chapter XII – Fund raising by issuance of debt securities by large corporate of Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, regarding issue and listing of Non – Convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper.**

This is with reference to the Chapter XII – Fund raising by issuance of debt securities by large corporate of the above-mentioned SEBI Circular dated August 10, 2021, in respect of issue and listing of Non – Convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper.

In this regard, we would like to inform you that the Company i.e. "Balaxi Pharmaceuticals Limited" does not fall under the definition of Large Corporate category as per the criteria specified in the aforesaid Circular as on March 31, 2023.

The details as required under Annexure XII – A of the aforesaid circular is enclosed.

We request you to take on record and acknowledge the same.

Yours Faithfully,

For **Balaxi Pharmaceuticals Limited**

**Udayan Shukla**  
(Company Secretary & Compliance Officer)  
Membership No.: F11744

Enclosure: Annexure XII – A

**Registered Office:**

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: [info@balaxi.in](mailto:info@balaxi.in) | Website: [www.balaxipharma.in](http://www.balaxipharma.in)

# Balaxi Pharmaceuticals Limited

## Annexure XII – A


**Format of the initial disclosure to be made by an entity identified as a Large Corporate (to be submitted to the stock exchange(s) within 30 days from the beginning of the FY)**

Sl. No.	Particulars	Details
1)	Name of the company	Balaxi Pharmaceuticals Limited
2)	CIN	L25191TG1942PLC121598
3)	Outstanding borrowing of company as on 31st March/ <del>31st December</del> , as applicable (in Rs. crore)	0.53 Crores*
4)	Highest credit rating during the previous FY along with name of the CRA	CRISIL BBB+/ Stable Name of the Credit Rating Agency: CRISIL Limited
5)	Name of stock exchange* in which the fine shall be paid, in case of shortfall in the required borrowing under the framework	Not Applicable

*Note: Outstanding borrowings excludes borrowings with original maturity of one year or less than one year.*

**We confirm that we are not a Large Corporate** as per the applicability criteria given under the Chapter XII of SEBI Operational circular dated August 10, 2021.

For **Balaxi Pharmaceuticals Limited**



**Udayan Shukla**  
(Company Secretary & Compliance Officer)  
Membership No.: F11744



**Amol Mantri**  
(Chief Financial Officer)

Email: [secretarial@balaxi.in](mailto:secretarial@balaxi.in)  
Phone: 040 - 23555300

Email: [amol@balaxi.com](mailto:amol@balaxi.com)  
Phone: 040 - 23555300

### Registered Office:

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: [info@balaxi.in](mailto:info@balaxi.in) | Website: [www.balaxipharma.in](http://www.balaxipharma.in)